We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
PPP2R1A is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
214.0
Number of samples
141
Samples
Sample
Description
TPM
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
414.4
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
400.6
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
343.1
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
333.2
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
333.1
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
328.9
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
323.9
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
311.3
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
308.4
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
299.9
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
299.2
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
296.5
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
293.5
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
292.7
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
291.8
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
291.5
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
288.9
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
286.7
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
284.2
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
281.6
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
280.0
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
276.1
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
273.8
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
271.9
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
271.5
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
269.1
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
268.1
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
267.0
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
266.5
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
259.2
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
257.6
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
256.7
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
255.6
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
254.2
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
252.6
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
252.1
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
251.4
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
250.6
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
249.0
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
248.7
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
248.6
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
246.6
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
243.5
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
242.1
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
241.9
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
240.1
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
240.0
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
239.7
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
239.1
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
238.7
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
237.9
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
237.8
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
236.0
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
235.9
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
234.5
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
234.2
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
232.1
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
229.8
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
228.9
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
228.6
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
226.3
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
221.5
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
220.6
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
219.0
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
218.5
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
216.9
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
215.6
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
214.4
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
214.0
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
213.4
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
213.1
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
212.2
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
211.7
TCGA-06-0129-01A
0 years, male, asian, stage:'--, dead, 1024 days
210.7
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
210.2
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
208.9
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
208.9
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
207.8
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
207.0
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
206.5
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
205.4
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
201.2
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
198.1
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
195.6
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
194.8
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
194.8
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
193.8
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
193.2
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
192.2
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
190.1
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
188.2
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
186.9
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
185.8
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
184.8
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
184.0
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
182.8
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
182.0
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
181.6
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
181.0
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
179.8
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
179.4
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
179.0
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
175.2
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
171.3
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
170.8
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
170.1
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
167.6
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
167.0
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
164.9
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
163.7
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
159.8
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
159.8
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
159.3
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
158.6
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
156.3
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
154.9
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
154.9
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
154.4
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
153.4
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
151.8
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
151.5
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
151.3
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
147.7
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
145.7
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
138.6
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
133.6
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
132.5
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
132.0
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
131.5
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
129.3
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
127.1
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
118.8
TCGA-26-5134-01A
0 years, male, white, stage:'--, alive, 167 days
117.9
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
116.9
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
107.7
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
104.7
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
101.4
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
96.3
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
92.1
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
PPP2R1A is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
24.4
Number of samples
58
Samples
Sample
Description
TPM
AK074
N, NA, stage:NA, alive, 300 days
44.2
AK213
N, NA, stage:NA, alive, 2010 days
43.1
AK043
N, NA, stage:NA, alive, 660 days
42.2
AK068
N, NA, stage:NA, alive, 360 days
38.1
AK098
N, NA, stage:NA, dead, 660 days
38.0
AK088
N, NA, stage:NA, dead, 360 days
37.6
AK100
N, NA, stage:NA, alive, 960 days
35.7
AK053
N, NA, stage:NA, dead, 300 days
35.6
AK226
N, NA, stage:NA, dead, 360 days
35.2
AK123
N, NA, stage:NA, dead, 180 days
34.8
AK133
N, NA, stage:NA, dead, 360 days
32.7
AK178
N, NA, stage:NA, dead, 240 days
32.7
AK089
N, NA, stage:NA, dead, 330 days
32.4
AK165
N, NA, stage:NA, alive, 360 days
32.2
AK158
N, NA, stage:NA, dead, 360 days
32.2
AK134
N, NA, stage:NA, dead, 360 days
29.8
AK142
N, NA, stage:NA, alive, 90 days
27.8
AK072
N, NA, stage:NA, dead, 150 days
27.8
AK188
N, NA, stage:NA, alive, 420 days
27.7
AK139
N, NA, stage:NA, dead, 270 days
27.1
AK055
N, NA, stage:NA, dead, 240 days
26.7
AK035
N, NA, stage:NA, dead, 210 days
26.1
AK227
N, NA, stage:NA, alive, 300 days
25.6
AK149
N, NA, stage:NA, dead, 420 days
25.3
AK173
N, NA, stage:NA, dead, 180 days
23.6
AK099
N, NA, stage:NA, dead, 420 days
23.5
AK091
N, NA, stage:NA, dead, 210 days
23.4
AK071
N, NA, stage:NA, dead, 540 days
22.7
AK185
N, NA, stage:NA, alive, 330 days
22.3
AK199
N, NA, stage:NA, alive, 1860 days
22.0
AK183
N, NA, stage:NA, alive, 360 days
21.0
AK085
N, NA, stage:NA, alive, 660 days
20.1
AK015
N, NA, stage:NA, alive, 720 days
20.1
AK079
N, NA, stage:NA, dead, 210 days
20.0
AK117
N, NA, stage:NA, dead, 210 days
19.9
AK236
N, NA, stage:NA, dead, 360 days
19.7
AK231
N, NA, stage:NA, dead, 240 days
19.3
AK218
N, NA, stage:NA, dead, 180 days
19.2
AK051
N, NA, stage:NA, dead, 360 days
19.1
AK167
N, NA, stage:NA, dead, 180 days
18.9
AK216
N, NA, stage:NA, dead, 360 days
18.2
AK076
N, NA, stage:NA, alive, 660 days
18.0
AK102
N, NA, stage:NA, alive, 1740 days
17.8
AK081
N, NA, stage:NA, dead, 180 days
17.8
AK103
N, NA, stage:NA, alive, 1320 days
17.2
AK205
N, NA, stage:NA, dead, 120 days
16.8
AK003
N, NA, stage:NA, dead, 600 days
16.7
AK195
N, NA, stage:NA, dead, 390 days
16.5
AK002
N, NA, stage:NA, dead, 570 days
16.3
AK041
N, NA, stage:NA, alive, 810 days
16.1
AK124
N, NA, stage:NA, alive, 1920 days
15.9
AK066
N, NA, stage:NA, alive, 960 days
15.5
AK030
N, NA, stage:NA, dead, 120 days
15.3
AK005
N, NA, stage:NA, dead, 240 days
15.3
AK006
N, NA, stage:NA, dead, 360 days
15.2
AK156
N, NA, stage:NA, dead, 330 days
14.3
AK153
N, NA, stage:NA, dead, 240 days
14.0
AK049
N, NA, stage:NA, dead, 180 days
14.0
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0204330003
Normal
1.0
CPT0204400003
Normal
1.0
CPT0204360003
Normal
1.0
CPT0204340003
Normal
0.9
CPT0204380003
Normal
0.9
CPT0204390003
Normal
0.9
CPT0204410003
Normal
0.9
CPT0204420003
Normal
0.9
CPT0204350003
Normal
0.8
CPT0204370003
Normal
0.7
CPT0217880003
Tumor
0.4
CPT0199770003
Tumor
0.2
CPT0206330003
Tumor
0.2
CPT0196850003
Tumor
0.2
CPT0190240004
Tumor
0.2
CPT0218670003
Tumor
0.2
CPT0104220003
Tumor
0.2
CPT0206880003
Tumor
0.2
CPT0224330003
Tumor
0.2
CPT0206450003
Tumor
0.2
CPT0221180003
Tumor
0.1
CPT0162140003
Tumor
0.1
CPT0189250003
Tumor
0.1
CPT0207030003
Tumor
0.1
CPT0209440003
Tumor
0.1
CPT0219080004
Tumor
0.1
CPT0225760003
Tumor
0.1
CPT0189570004
Tumor
0.1
CPT0201710003
Tumor
0.1
CPT0168270003
Tumor
0.1
CPT0104330003
Tumor
0.1
CPT0207090003
Tumor
0.1
CPT0218770003
Tumor
0.1
CPT0182580003
Tumor
0.1
CPT0189850004
Tumor
0.1
CPT0182500003
Tumor
0.0
CPT0206110003
Tumor
0.0
CPT0217100003
Tumor
0.0
CPT0087680003
Tumor
0.0
CPT0167860004
Tumor
0.0
CPT0208980003
Tumor
0.0
CPT0093510003
Tumor
0.0
CPT0182550003
Tumor
0.0
CPT0125510003
Tumor
0.0
CPT0078580003
Tumor
0.0
CPT0189460003
Tumor
0.0
CPT0093590003
Tumor
0.0
CPT0205570003
Tumor
0.0
CPT0217710008
Tumor
0.0
CPT0205670004
Tumor
0.0
CPT0217000004
Tumor
0.0
CPT0161730003
Tumor
0.0
CPT0168720003
Tumor
0.0
CPT0125570003
Tumor
0.0
CPT0162100003
Tumor
0.0
CPT0218890004
Tumor
0.0
CPT0217190003
Tumor
0.0
CPT0218960004
Tumor
-0.1
CPT0162020003
Tumor
-0.1
CPT0190360004
Tumor
-0.1
CPT0217060003
Tumor
-0.1
CPT0125220003
Tumor
-0.1
CPT0206780003
Tumor
-0.1
CPT0087950003
Tumor
-0.1
CPT0168380003
Tumor
-0.1
CPT0167750004
Tumor
-0.1
CPT0123530003
Tumor
-0.1
CPT0167970003
Tumor
-0.1
CPT0205890003
Tumor
-0.1
CPT0205450004
Tumor
-0.1
CPT0218690004
Tumor
-0.1
CPT0168590003
Tumor
-0.1
CPT0079790003
Tumor
-0.1
CPT0168830003
Tumor
-0.1
CPT0167530003
Tumor
-0.1
CPT0093360003
Tumor
-0.1
CPT0205780003
Tumor
-0.1
CPT0189750004
Tumor
-0.1
CPT0175060003
Tumor
-0.1
CPT0228220003
Tumor
-0.1
CPT0206230003
Tumor
-0.2
CPT0224390004
Tumor
-0.2
CPT0087730003
Tumor
-0.2
CPT0171580008
Tumor
-0.2
CPT0064890003
Tumor
-0.2
CPT0168080003
Tumor
-0.2
CPT0225730003
Tumor
-0.2
CPT0189650004
Tumor
-0.2
CPT0092440003
Tumor
-0.2
CPT0071100003
Tumor
-0.2
CPT0089150003
Tumor
-0.2
CPT0206000004
Tumor
-0.2
CPT0167640003
Tumor
-0.2
CPT0186100003
Tumor
-0.2
CPT0093450003
Tumor
-0.2
CPT0064650003
Tumor
-0.2
CPT0127480003
Tumor
-0.2
CPT0002410011
Tumor
-0.2
CPT0087570003
Tumor
-0.3
CPT0127420003
Tumor
-0.3
CPT0218330004
Tumor
-0.3
CPT0218830004
Tumor
-0.3
CPT0093550003
Tumor
-0.3
CPT0168480003
Tumor
-0.3
CPT0224600003
Tumor
-0.4
CPT0206560003
Tumor
-0.4
CPT0224540004
Tumor
-0.4
CPT0206670004
Tumor
-0.4
CPT0216920008
Tumor
-0.4
CPT0217430008
Tumor
-0.5
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.